Funds and ETFs Hangzhou Tigermed Consulting Co., Ltd
Equities
300347
CNE100001KV8
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
56.87 CNY | -2.20% | -0.05% | +3.46% |
Apr. 25 | Hangzhou Tigermed Consulting’s Profit Down 59% in Q1 | MT |
Apr. 25 | Hangzhou Tigermed Consulting Co., Ltd Reports Earnings Results for the First Quarter Ended March 30, 2024 | CI |
ETFs positioned on Hangzhou Tigermed Consulting Co., Ltd
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 7 M€ | +5.57% | - | |
0.00% | 7 M€ | +0.11% | - | |
0.00% | 8 M€ | +0.94% | - | |
0.00% | 15 M€ | +21.38% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+3.46% | 6.39B | |
+64.23% | 62.59B | |
-2.31% | 41.18B | |
+45.72% | 40.29B | |
-8.29% | 27.9B | |
+11.97% | 26.21B | |
-21.16% | 19.09B | |
+7.54% | 13.08B | |
+27.17% | 12.05B | |
+25.72% | 12.26B |
- Stock Market
- Equities
- 300347 Stock
- Funds and ETFs Hangzhou Tigermed Consulting Co., Ltd